KIT and neoplasm: Just as nowadays the measurement of allele burden of the KIT D816V mutation has become an important predictor of treatment response assessment [182] and survival [125], further analysis of the VAF for these later genes might provide a more reliable marker for assessing tumour burden as compared to other clinical and/or laboratory parameters, which can be also altered by medication or intercurrent processes (e.g., infectious and/or allergic diseases) [184,185,186].